Drug Profile
Research programme: alpha-emitting monoclonal antibody radiopharmaceuticals - Actinium Pharmaceuticals
Alternative Names: AA-A225; Ac-225 labeled anti-A33 monoclonal antibody; Ac-225-labeled anti-CD45 monoclonal antibody; Ac-255 labeled AA; Actimab-B; Actimab-Br; Actimab-C; Actimab-P; Actinium-225 labeled daratumumab; anti-A33 monoclonal antibody Ac-225; anti-CD45 monoclonal antibody BC8-Ac-225Latest Information Update: 21 Nov 2022
Price :
$50
*
At a glance
- Originator Fred Hutchinson Cancer Research Center
- Developer Actinium Pharmaceuticals; Memorial Sloan-Kettering Cancer Center
- Class Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
- Mechanism of Action Angiogenesis inhibitors; Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Multiple myeloma
- No development reported Brain cancer; Colorectal cancer; Haematological malignancies; Prostate cancer
Most Recent Events
- 27 Sep 2022 Preclinical development for Multiple-myeloma is ongoing in USA (Parenteral) (Actinium Pharmaceuticals pipeline, September 2022)
- 28 Apr 2022 No recent reports of development identified for preclinical development in Brain-cancer in USA (Parenteral)
- 28 Apr 2022 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (Parenteral)